Liver X receptor agonist T0901317 reverses resistance of A549 human lung cancer cells to EGFR‐TKI treatment

Epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) is effective in lung cancer patients carrying sensitive EGFR mutations. In this study, we investigated if liver X receptor (LXR) agonist T0901317 could reverse the resistance of lung cancer cell lines A549 and H1650 to EGFR‐TKI tr...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:FEBS Open Bio
Asıl Yazarlar: Cao, Haixia, Yu, Shaorong, Chen, Dan, Jing, Changwen, Wang, Zhuo, Ma, Rong, Liu, Siwen, Ni, Jie, Feng, Jifeng, Wu, Jianzhong
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2016
Konular:
Research Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5221460/
https://ncbi.nlm.nih.gov/pubmed/28097086
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/2211-5463.12147
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller